There are limited strategies for the treatment of hepatocelllar carcinomas (HCCs).
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer mortality worldwide (1) . Currently, surgery is the most effective treatment for HCC. However, tumor recurrence after a curative liver resection is very high, and the 5-year survival rate remains at only 10% (2) . Moreover, because the majority of patients with HCC are diagnosed at a late disease stage, potentially curative therapies, including chemotherapy, chemoembolization, ablation and proton beam therapy, are frequently ineffective. Sorafenib (Nexavar), the first clinically approved targeted drug therapy for HCC, could only extend the overall survival by 2-3 months (3). Thus, it remains an urgent need for effective, life-prolonging strategies in the management of HCC patients.
Immunotherapy based on T cells modified with a chimeric antigen receptor (CAR) has been demonstrated as a promising strategy for cancer treatment (4) . CAR T cells can specifically recognize tumor-associated antigen and eliminate tumor cells in a non-major histocompatibility complex-restricted manner. Several pilot clinical trials using CAR T cells have recently been reported with promising clinical outcomes (5) .
GPC3 is a member of the glypican family of heparan sulfate (HS) proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor.
GPC3 plays an important role in cellular growth, differentiation and migration (6) .
Multiple studies have demonstrated that GPC3 is an attractive liver-cancer-specific target because it is highly expressed in HCC but limited expressed in normal tissues (7) . Currently, GPC3-targeted immunotherapeutic strategies utilizing antibodies or a (8) (9) (10) (11) (12) . The clinical data of the monoclonal antibody GC33 indicated that it was well tolerated in advanced HCC, suggesting that GPC3 is a relatively safe target. However, according to experimental knockdown results, GPC3 is not a lethal gene to HCC cells (13) . Moreover, the naked antibody could not completely eliminate tumors in mouse models, and no partial or complete response was observed in the fifteen patients evaluated during the phase I clinical trial of GC33, suggesting that the therapeutic effects of a naked antibody may not be potent enough for curative treatment of HCC (14) . In the phase I clinical trial of a GPC3-derived peptide vaccine for HCC patients, the median overall survival appeared to positively correlate with the GPC3-specific CTL frequencies, suggesting that GPC3-targeted T cells could be potential agents for HCC treatment (12) .
However, GPC3-based, CAR-engineered T cells have never been reported. Therefore, in this study, we developed GPC3-specific CAR T cells and explored their potential for HCC treatment.
Research. 
Materials and Methods

Construction of lentiviral vectors encoding CARs
The sequence encoding the anti-GPC3 scFv antibody in the VL-VH orientation ( Supplementary Fig. S1 ), based on the sequence of GC33, which recognizes the C-terminal region of GPC3 (8) , was obtained by splicing PCR and the overlap extension technique. As shown in Figure 1A , the αGPC3-Z CAR (first generation) comprising the scFv GPC3 linked to the human CD8α hinge and transmembrane domain (nucleotides 412-609, GenBank NM 001768. at the 3' end and were ligated into the third generation non-self-inactivating EF-1α promoter-based lentiviral expression vector pWPT-eGFP (17) . The primers are listed in Supplementary Table S1 .
Cell lines
Human HCC cell lines (HepG2, Hep3B, PLC/PRF/5 and SK-HEP-1) and 293T
were obtained from the American Type Culture Collection (ATCC, Manassas, VA).
Huh-7 cell line was obtained from the RIKEN Cell Bank (Tsukuba, Japan). These cell lines were tested and authenticated by DNA profiling for polymorphic short-tandem repeat (STR) markers. For bioluminescence assays, Huh-7 cells with enforced expression of firefly luciferase (fLuc + ) were established. 293T and HCC cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Gibco, UK). All cells were routinely tested for mycoplasma contamination.
Lentivirus production
Recombinant lentiviral particles were produced by a calcium phosphate transfection system (17) . Lentiviral particles were concentrated 30-fold by ultracentrifugation (Beckman Optima™ XL-100 K, Beckman, Germany) for 2 h at 28,000 rpm. 
Isolation, activation, transduction and expansion of human T cells
Western blot analysis
The cell lysate was denatured and electrophoresed by SDS-PAGE. The samples were then transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA) and immunoblotted with the targeted antibodies.
Cytotoxicity assays in vitro
The specific cytotoxicity of CAR-modified T cells towards various HCC cells at the different effector : target ratios of 3 : 1 
Cytokine release assays
The IFN-γ and IL-2 cytokines secreted by the varying genetically modified T cells were measured using an ELISA kit (MultiSciences Biotechnology, Hangzhou, China).
Xenograft models of human hepatocellular carcinoma
Six-to eight-week-old NOD/SCID mice were housed and treated under specific 
Bioluminescence imaging
Isoflurane-anesthetized animals were imaged using the IVIS system (IVIS, Xenogen, Alameda, CA) followed by the intraperitoneally (i. Image software (Caliper Life Sciences, Hopkinton, MA).
Immunohistochemistry
The HLiv-HCC150CS-01 tissue microarray (Outdo Biotech, Shanghai, China) and sections of the normal kidney and gastric glands were immunostained using an anti-GPC3 antibody (mAb 1G12, BioMosaics Inc, Burlington, VT). To assess the persistence of the administrated human T cells in xenografts, the sections of formalin-fixed, paraffin-embedded tumor tissues were immunostained using an anti-CD3 antibody (Thermo Scientific RM-9107-S0).
Statistical analysis
Statistical analysis was performed by 2-way repeated measures ANOVA with Bonferroni post-tests for the tumor burden (tumor volume, tumor weight and photon counts). Differences in the absolute number of various transferred T cells were evaluated by Student's t-test. The overall survival statistics were calculated using the log-rank test (19) . GraphPad Prism 5.0 was used for the statistical calculations. P < 0.05 (*), P < 0.01 (**) and P < 0.001(***) was considered statistically significant. 
Results
Generation of CAR-GPC3 T cells by lentiviral vector transduction
As shown in Figure 1A , the lentiviral expression vectors encoding the GPC3-targeted CARs including αGPC3-Z, αGPC3-28BBZ or negative control CARs including αGPC3-DZ and 2D3-28BBZ efficiently transduced human T cells to co-express the CAR protein and eGFP using the "self-cleaving" F2A peptide, respectively. The genetically modified T cells began to expand after activation. On day 7, the expression of the different CARs in the transduced T cells was demonstrated through eGFP expression. The transduction efficiencies were about 55% (Fig. 1B) . According to viable cell counting assays (trypan blue exclusion), the αCD3/αCD28-coated beads could induce 200-300 fold expansions of CAR-modified T cells on day 18. In the presence of OKT3 (100 ng/ml) and recombinant human IL-2 (300 U/ml), the expansion could be further increased by 10-20 fold (Fig. 1C) after subsequent stimulation for 7 days with cells of γ-irradiated K562-based artificial antigen-presenting cells (aAPC) (referred to as aK562-64/86) which express the membrane-bound extra-domains of CD64 and CD86 ( Supplementary Fig. S2 ). To determine the antigen-specific expansion, the well-known GPC3-positive Huh-7 cells and GPC3-negative SK-HEP-1 cells were used for specific stimulations on day 18.
The results indicated that T cells expressing αGPC3-28BBZ were expanded by the stimulation of GPC3-positive Huh-7 cells but not by GPC3-negative SK-HEP-1 cells.
Additionally, both GPC3
+ and GPC3 -HCC cell lines failed to elicit the expansion of mock or 2D3-28BBZ transduced T cells (Fig. 1D ).
Cytokines produced by GPC3-targeted CAR T cells
Surface expression of GPC3 on five HCC cell lines was determined. The results of FACS and western blot ( Fig. 2A) confirmed that SK-HEP-1 had no GPC3 expression, and the other four HCC cell lines had varying levels of GPC3 expression. In the cytokine production assay, greater amounts of IL-2 ( Fig. 2B) and IFN-γ (Fig. 2C) were produced by αGPC3-28BBZ CAR T cells than αGPC3-Z CAR T cells or the control T cells including mock, αGPC3-DZ or 2D3-28BBZ transduced T cells, when cocultured with GPC3-positvie cells. However, almost no induction of IL-2 or IFN-γ was observed when any of the engineered T cells were cocultured with SK-HEP-1 cells (Fig. 2B, C) . Intriguingly, there was a positive correlation between IFN-γ secretion in GPC3-redirected CAR T cells transfected with either αGPC3-28BBZ or αGPC3-Z and the MFI of GPC3 expression on the target cells (Fig. 2D) .
In vitro cytotoxicity of T cells redirected to GPC3 on HCC cells
To determine whether T cells targeting GPC3 could specifically recognize and kill 
It was reported that two types of soluble GPC3 (sGPC3) exist in the blood serum of patients with HCC (20, 21) . One is the N-terminal region of GPC3 (GPC3N, residues: S25-R358); the other is the full-length GPC3 without GPI (GPC3ΔGPI, residues: Q25-S560). To elucidate whether sGPC3 can prevent the activation and functional activity of the GPC3-targeted CAR T cells, the cytotoxic activities of the αGPC3-28BBZ-modified T cells towards Huh-7 cells in the presence or absence of three types of recombinant sGPC3 were determined. The results indicated that the GC33 binding peptide fusion protein and GPC3ΔGPI, but not GPC3N, could inhibit the cytotoxic activities of the αGPC3-28BBZ-modified T cells. However, this suppression was mild, as the highest inhibition ratio was approximately 10% even at a concentration of 1000 ng/ml GPC3ΔGPI (Fig. 3B) .
CAR T cells redirected to GPC3 suppress the tumorigenesis of subcutaneous
Huh-7 xenografts
NOD/SCID mice were coinjected s.c. with the Huh-7 tumor cells and transduced T cells at an E : T ratio of 1 : 1 on the right flanks, with an additional group receiving the αGPC3-28BBZ T cells at an E : T ratio of 1 : 2. The results indicated that two out of the six mice were tumor-free in the group that received αGPC3-Z CAR T cells, while all mice were tumor-free in the group that received αGPC3-28BBZ CAR T cells, even at an E : T ratio of 1 : 2 ( Supplementary Fig. S3A ). In contrast, tumor outgrowth was observed in all mice in the control groups ( Supplementary Fig. S3B ). The results indicated the αGPC3-28BBZ CAR T cells displayed a significantly stronger lytic Fig. S4A ). The antitumor effect of the αGPC3-28BBZ CAR T cells was very significant compared with the control groups, respectively (P < 0.001) (Fig.4A, Supplementary Fig. S4B ). These results suggested that GPC3-targeted CAR T cells could specifically eliminate Huh-7 cells in vivo.
To elucidate whether the in vivo cancer cell eliminating ability of αGPC3-28BBZ CAR T cells is dependent on the expression level of GPC3, mice bearing PLC/PRF/5 xenografts were also treated with the genetically modified T cells. Compared with the control groups, the αGPC3-28BBZ CAR T cells could significantly suppress the growth of PLC/PRF/5 tumors (Fig. 4B) . At the end of the study (day 47), the mice bearing PLC/PRF/5 tumors treated with αGPC3-28BBZ CAR T cells still carried residual tumors (Supplementary Fig. S4C ). The tumors treated with αGPC3-28BBZ CAR T cells were significantly smaller in weight than those in the control groups (αGPC3-28BBZ vs saline, P = 0.0332; αGPC3-28BBZ vs mock, P = 0.021; αGPC3-28BBZ vs 2D3-28BBZ, P = 0.0367; Supplementary Fig. S4D ). The results of these two models implicated that the cytotoxic activities of GPC3-targeted CAR T cells were dependent on the GPC3 expression level on the target cells.
Previous studies have indicated that the persistence of transferred T cells in vivo is highly correlated with tumor regression (22, 23) . Therefore, we also detected the (Fig. 6A) . In the third week after the first dose of T cell administration, the mice in the three control groups had swollen abdomens, while the mice of the αGPC3-28BBZ CAR T cell treated group had the normal abdomen ( Supplementary Fig. S5 ). At the end of this study, 3 
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CAR T cells survived for longer than 60 days while the median survival durations of the saline, mock and 2D3-28BBZ-treated mice were 33 days, 34 days and 39 days, respectively (Fig. 6D) .
Discussion
In this study, we developed GPC3-targeted CAR T cells with or without the costimulatory signaling domains of CD28 and CD137. Both types of GPC3-targeted CAR T cells could specifically destroy the HCC cells in an antigen-dependent manner.
Similar to previous reports (25) , the αGPC3-28BBZ CAR T cells that had the costimulatory signaling domains displayed a significantly stronger cytotoxic activity against the GPC3 + HCC cells than the αGPC3-Z CAR T cells did, suggesting that the intracellular CD28 and CD137 costimulatory domains contributed to the increased cytotoxic activities.
Our data on established Huh-7 subcutaneous and orthotopic xenografts indicated A major concern regarding CAR T cells, especially when the costimulatory signaling domain of CD28 or CD137 is included, is the on-target off-tumor effect.
Previously, one breast cancer patient died after the treatment with CAR T cells redirected to Erbb2 due to the expression of this receptor in lung tissues (27) . As we know, one of the major challenges for cancer treatment lies in its heterogeneity. Several testis-antigens have been targeted by T cell-based immunotherapy. However, most of the testis antigens are heterogeneously expressed in the tumor tissue (32) . In the tumor tissue microarray of 75 primary HCC patients, the different levels of GPC3 expression were evaluated by two experienced pathologists using a 4-point scale according to the staining intensity ( Supplementary   Fig. S8A ). Similar to previous reports (7, 33) , our data indicated that GPC3 was expressed in 70.7% (53 out of 75) of HCC patients (Supplementary Fig. S8B ). In GPC3-positive patients, 77% (41 out of 53) of patients carried high levels of GPC3 expression (score≥2). Importantly, unlike testis-antigen, in patients carrying a high level of GPC3 expression, GPC3 appeared to be homogenously expressed in HCC tissues with a mean rate of GPC3-positive hepatoma cells equal to 88% (Supplementary Fig. S8C ). This will be an important factor in the long-term clinical efficacy of GPC3-directed CAR T cells.
Taken together, the results of this study constitute the first report concerning CAR T cells redirected to GPC3 and the first report about HCC treatment using CAR T cells. With their potent cancer cell-eliminating capacity, GPC3-targeted CAR T cells may be a promising therapeutic option for HCC treatment. 
